Peter McLaughlin, Susan Lynch Foster
The ubiquitous buzz of AI, and more practically machine learning, impacts technology advances in the health arena as much as any other. Deep Mind and similar programs have demonstrated the ability to analyze medical images faster and with often better accuracy than trained professionals.
The data processing power can help recognize population health risks faster, and it can help provide a more nuanced diagnosis and treatment plan for an individual patient, given certain personal health data. This extends, too, to personal health apps that people use to track their health, whether this is for management of hypertension, diabetes, or any number of other health conditions.
AI can accelerate the discovery of druggable targets and new compounds of interest. Clinical trials can leverage AI to speed up data analyses and decrease the time required to get new drugs or devices approved, as well as improving the trial experience for patients.
But what of all the personal data being fed into the maw of such systems? The European Data Protection Board and other EU institutions are rushing to understand – and with the AI Act, regulate — how AI is trained and how it processes and retains the data it ingests. In the U.S., there are at least two significant regulators depending on the nature of the personal health data processing. And while these two U.S. agencies (HHS for “regulated” health data and the FTC for “other- or un-regulated health data”) coordinate, they nonetheless impose different rules and requirements.
Organizations of all sectors and sizes capture personal health data in different contexts. It may be for employment purposes or as a product or service offering from a traditional healthcare org or a health tech firm. Join our expert panel and leave with:
- An understanding of which rules apply in the EU and the U.S.
- The ability to distinguish which regulator in the U.S. would have jurisdiction over your product and thus the applicable rules
- Incorporating Privacy by Design into any AI engines analyzing personal health data
Susan Lynch Foster, Technology Data Privacy Director, GCS, AstraZeneca, UK
Peter McLaughlin, Partner – Data Privacy & Innovation, Rimon Law
Reading Materials:
